➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Medtronic
Johnson and Johnson
Moodys
Baxter

Last Updated: August 5, 2021

DrugPatentWatch Database Preview

PAMELOR Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Pamelor patents expire, and what generic alternatives are available?

Pamelor is a drug marketed by Specgx Llc and is included in two NDAs.

The generic ingredient in PAMELOR is nortriptyline hydrochloride. There are twelve drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the nortriptyline hydrochloride profile page.

Drug patent expirations by year for PAMELOR
Drug Prices for PAMELOR

See drug prices for PAMELOR

Drug Sales Revenue Trends for PAMELOR

See drug sales revenues for PAMELOR

Recent Clinical Trials for PAMELOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Central Michigan UniversityN/A
Sheppard Pratt Health SystemN/A
Federal University of Rio Grande do SulPhase 4

See all PAMELOR clinical trials

Pharmacology for PAMELOR
Paragraph IV (Patent) Challenges for PAMELOR
Tradename Dosage Ingredient NDA Submissiondate
PAMELOR CAPSULE;ORAL nortriptyline hydrochloride 018013

US Patents and Regulatory Information for PAMELOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-001 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-003 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-002 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-004 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Specgx Llc PAMELOR nortriptyline hydrochloride SOLUTION;ORAL 018012-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PAMELOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-001 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-004 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-003 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-002 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Specgx Llc PAMELOR nortriptyline hydrochloride SOLUTION;ORAL 018012-001 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Medtronic
Johnson and Johnson
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.